INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, AND CONTROL
Mesa Laboratories Inc
MLAB
Mesa Laboratories Inc manufactures life sciences tools and critical quality control solutions. It operates in four divisions: i) Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. ii) Clinical Genomics division develops, manufactures, and sells sensitive, low-cost, high-throughput genetic analysis tools and related consumables. iii) The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. iv) The Calibration Solutions division develops, manufactures, sells, and services quality control products.
Last trade$134.30
Day change+$0.21 (+0.16%)
Day range$131.86 – $136.16
Volume55,286
Market cap$754M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$753.66M
Price / earnings
113.08×
Price / book
3.87×
Price / sales
3×
EV / sales
3.43×
EV / EBITDA
17.68×
Profitability
Earnings per share
$1.19
Return on assets
1.63%
Return on equity
3.43%
Dividend yield
0.47%
Liquidity and leverage
Debt / equity
0.68×
Current ratio
1.9×
Quick ratio
1.39×
Cash ratio
0.43×
Cash flow
Price / cash flow
14.62×
Price / free cash flow
15.24×
Free cash flow
$49.45M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MLAB, quarterly periods
Line item
Q2 FY2027 Sep 30, 2026
Q1 FY2027 Jun 30, 2026
Q4 FY2026 Mar 31, 2026
Q3 FY2026 Dec 31, 2025
Q2 FY2026 Sep 30, 2025
Q1 FY2026 Jun 30, 2025
Q4 FY2025 Mar 31, 2025
Q3 FY2025 Dec 31, 2024
Revenue
$62.34M
$60.14M
$63.72M
$65.13M
$60.74M
$59.54M
$62.14M
$62.84M
Cost of revenue
$22.46M
$21.13M
$21.52M
$23.33M
$23.41M
$22.6M
$23.72M
$23.09M
Gross profit
$39.88M
$39.01M
$42.21M
$41.8M
$37.33M
$36.94M
$38.41M
$39.75M
Selling, general and administrative
$26.44M
$27.26M
$34.21M
$28.79M
$27.56M
$28.89M
$31.85M
$28.92M
Research and development
$5.05M
$4.73M
$5.25M
$5.03M
$5.05M
$4.98M
$5.1M
$5.05M
Total operating expenses
$31.49M
$31.98M
$39.46M
$33.82M
$32.61M
$33.88M
$36.94M
$33.98M
Operating income
$8.39M
$7.03M
$2.75M
$7.98M
$4.72M
$3.06M
$1.47M
$5.78M
Interest expense
-$2.14M
-$2.36M
-$2.6M
-$3.04M
-$2.86M
-$2.2M
-$2.52M
-$2.84M
Income before taxes
$6.03M
$4.35M
-$1.59M
$4.6M
$2M
$7.01M
$461K
-$2.22M
Income taxes
$1.69M
$1.52M
$2.54M
$966K
-$477K
$2.27M
$7.58M
-$541K
Net income
$4.34M
$2.83M
-$4.14M
$3.63M
$2.48M
$4.74M
-$7.11M
-$1.68M
Net income attributable to common shareholders
$4.34M
$2.83M
-$4.14M
$3.63M
$2.48M
$4.74M
-$7.11M
-$1.68M
EBITDA
$13.95M
$12.68M
$8.5M
$13.69M
$10.57M
$9.02M
$8.97M
$11.28M
Basic earnings per share
$0.77
$0.50
-$0.75
$0.66
$0.45
$0.87
-$1.31
-$0.31
Diluted earnings per share
$0.75
$0.49
-$0.74
$0.65
$0.45
$0.85
-$1.33
-$0.31
Recent news
Company coverage with links to the original publishers.
Mesa Laboratories stock plummeted 19.5% on May 27, 2026, after reporting Q4 fiscal 2026 results. While the company beat expectations on adjusted operating income per share ($3.30 vs. $1.54 estimate), sales of $63.72 million fell short of Wall Street expectations by approximately $1.48 million. CEO Siddhartha Kadia is conducting an internal review and will provide full-year guidance with the Q2 report.
Mesa Laboratories, Inc. (MLAB) announced a regular quarterly dividend of $0.16 per share, payable on June 16, 2025. The company is a global leader in life science tools and quality control solutions for the pharmaceutical, healthcare, and medical device industries.
Mesa Laboratories, Inc. reported its second quarter fiscal year 2025 results, with revenues increasing 8.8% year-over-year. The company's Biopharmaceutical Development and Calibration Solutions divisions saw strong growth, while the Clinical Genomics division faced headwinds in China and North America.
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock, payable on December 16, 2024, to shareholders of record at the close of business on November 29, 2024.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
Declared upcoming dividend$0.16 per share
Declared
Oct 8, 2026
Ex-dividend
Nov 30, 2026
Pay date
Dec 15, 2026
Ex-dividend
Amount / share
Pay date
Type
Aug 31, 2026
$0.16
Sep 15, 2026
recurring
May 29, 2026
$0.16
Jun 15, 2026
recurring
Feb 27, 2026
$0.16
Mar 16, 2026
recurring
Nov 28, 2025
$0.16
Dec 15, 2025
recurring
Aug 29, 2025
$0.16
Sep 15, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.